Heidelberg Engineering and RetInSight to Offer AI-Based OCT Fluid Quantification Solution
Heidelberg Engineering and RetInSight announced they intend to interface the RetInSight AI-based fluid monitor application with the Heidelberg Engineering product portfolio, using cloud exchange and application marketplace technologies.
RetInSight utilizes a novel, proprietary algorithm, that supports the detection, localization and quantification of intra- and subretinal fluid in OCT images in an accurate and reliable manner.1 The fluid monitor application aims to facilitate early diagnosis and therapeutic guidance in the most common diseases of the retina, i.e., neovascular age-related macular degeneration (AMD), diabetic macular edema (DME),2,3 and retinal vein occlusion (RVO). In combination with the Heidelberg Eye Explorer HEYEX 2 technology, RetInSight fluid monitor application will offer an efficient clinical workflow.
“This automated service provides precision and speed beyond human expert capacity. It will display intuitive results through a user-friendly RetInSight viewer or via an ePDF report within the HEYEX 2 platform”, Dr. Amir Sadeghipour, Chief Technology Officer of RetInSight, said in a company news release.
RetInSight’s algorithm was designed under a quality management system, according to ISO 13485:2016, and CE marking in conformance with the EU Medical Device Regulation is anticipated in June 2021. In the United States, regulatory submission is targeted for 2022.
The aim of the HEYEX 2 workflow interface with the cloud-based RetInSight service is to enable SPECTRALIS users to send OCT volume scans for analysis quickly and securely. Heidelberg Engineering also plans to provide a workflow solution for legacy HEYEX users, as well as for third party OCT devices.
“The availability of the RetInSight application within the HEYEX 2 image management platform will lead to highly efficient disease management. Combining Heidelberg Engineering image quality with this novel AI-service will empower SPECTRALIS owners to improve patient care,” Martin Schinkmann, Head of Product Management for HEYEX 2 and HEYEX PACS and Managing Director of MedicalCommunications, a Heidelberg Engineering company, said in the news release.
1 Schmidt-Erfurth U, Sadeghipour A, Gerendas BS, Waldstein SM, Bogunović H. Artificial intelligence in retina [Prog Retin Eye Res. 2018; 67:1-29] https://www.sciencedirect.com/science/article/pii/S1350946218300119?via%3Dihub
2 Michl M, Fabianska M, Seeböck P, et al. Automated quantification of macular fluid in retinal disease and their response to anti-VEGF therapy. Br. J Ophthalmology. October 2020: bjophthalmology-2020-317416
3 Roberts PK, Vogel WD, Gerendas BS, et al. Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning. JAMA Ophthalmol. 2020 Sep 1; 138(9): 945-953